Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease
The DOI matches its Crossref record; 40 of the 41 references it cites were found in a registry or an index.
Abstract
Gene dosage of the apolipoprotein E (APOE) epsilon 4 allele is a major risk factor for familial Alzheimer disease (AD) of late onset (after age 60). Here we studied a large series of 115 AD case subjects and 243 controls as well as 150 affected and 197 unaffected members of 66 AD families. Our data demonstrate a protective effect of the epsilon 2 allele, in addition to the dose effect of the epsilon 4 allele in sporadic AD. Although a substantial proportion (65%) of AD is attributable to the presence of epsilon 4 alleles, risk of AD is lowest in subjects with the epsilon 2/epsilon 3 genotype, with an additional 23% of AD attributable to the absence of an epsilon 2 allele. The opposite actions of the epsilon 2 and epsilon 4 alleles further support the direct involvement of APOE in the pathogenesis of AD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Common variants of the apolipoprotein E gene (APOE) influence the risk of Alzheimer’s disease: APOE4 is linked to high risk, APOE3 is considered to confer a neutral risk, and APOE2 is associated with relative protection.2–5”
From APOE3 Christchurch Heterozygosity and Autosomal Dominant Alzheimer’s Disease (2024) · cites this paper as [5]
Experimental — accuracy not yet measuredIn the citing paper
“APOE, the major susceptibility gene for late-onset AD, has three common alleles (APOE2, 3, and 4).”
From Resistance to autosomal dominant Alzheimer’s disease in an APOE3 Christchurch homozygote: a case report (2019) · cites this paper as [10]
In the citing paper
“Compared to the most common APOE3/3 genotype, which is considered neutral with regard to AD risk, APOE2 is associated with a lower AD risk and older age at dementia onset, and each additional copy of APOE4 is associated with a higher risk and younger age at onset.10”
From Resistance to autosomal dominant Alzheimer’s disease in an APOE3 Christchurch homozygote: a case report (2019) · cites this paper as [10]
In the citing paper
“Apolipoprotein E (APOE), the major susceptibility gene for late-onset Alzheimer’s disease (AD), has three common alleles (APOE2, 3, and 4), giving rise to six genotypes (APOE2/2, 2/3, 3/3, 2/4, 3/4, and 4/4).”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [2]
In the citing paper
“while the presence of one or two copies of the APOE2 allele is associated with a lower risk of Alzheimer’s dementia and an older mean age at dementia onset1–4.”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [2]
38 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429
Self-citationGoate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
Self-citationStrittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1977 · Cited by 4,268
Self-citationApolipoprotein E: Cholesterol Transport Protein with Expanding Role in Cell Biology
Mahley, R. W. (1988) · Science · doi:10.1126/science.3283935 · Cited by 4,028
Association of apolipoprotein E allele ϵ4 with late‐onset familial and sporadic Alzheimer's disease
Saunders, A. M., Strittmatter, W. J., Schmechel, D., St. George-Hyslop, P. H., Pericak-Vance, M. A., Joo, S. H., Rosi, B. L., Gusella, J. F., Crapper-MacLachlan, D. R., Alberts, M. J., et al. (1993) · Neurology · doi:10.1212/wnl.43.8.1467 · Cited by 3,786
Self-citationDiagnosis of Alzheimer's Disease
Khachaturian, Z. S. (1985) · Archives of Neurology · doi:10.1001/archneur.1985.04060100083029 · Cited by 2,499
Schmechel, D. E., Saunders, A. M., Strittmatter, W. J., Crain, B. J., Hulette, C. M., Joo, S. H., Pericak-Vance, M. A., Goldgaber, D., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.20.9649 · Cited by 1,525
Self-citationStrittmatter, W. J., Weisgraber, K. H., Huang, D. Y., Dong, L. M., Salvesen, G. S., Pericak-Vance, M., Schmechel, D., Saunders, A. M., Goldgaber, D., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.17.8098 · Cited by 1,363
Self-citationThe Genetic Defect Causing Familial Alzheimer's Disease Maps on Chromosome 21
St George-Hyslop, P. H., Tanzi, R. E., Polinsky, R. J., Haines, J. L., Nee, L., Watkins, P. C., Myers, R. H., Feldman, R. G., Pollen, D., Drachman, D., et al. (1987) · Science · doi:10.1126/science.2880399 · Cited by 1,163
Self-citation
Research works printed but not linked: 2
- Cornoni-Huntley, J., Blazer, D.G., Service, C. & Farmer, M.E. in Established population for epidemiologic studies of the elderly. Volume II (eds Cornoni-Huntley, J. et al.) 1–7 (NIH publication 90–495, Bethesda, 1990).
- Rothman, K.J. Modern Epidemiology. 38–39, 76 (Little, Brown & Company, Boston, 1986).
Cited by
Items 701–800 of 1,029
Griffin, E. F., Scopel, S. E., Stephen, C. A., Holzhauer, A. C., Vaji, M. A., Tuckey, R. A., Berkowitz, L. A., Caldwell, K. A., & Caldwell, G. A. (2019) · Disease Models & Mechanisms · doi:10.1242/dmm.037218 · Cited by 62
“The APOEε2 allele appears to provide protection against AD via a mechanism that consists of more than the absence of the APOEε4 allele (Corder et al., 1994; Talbot et al., 1994).”
InfluentialStratman, N. C., Castle, C. K., Taylor, B. M., Epps, D. E. V., Melchior, G. W., & Carter, D. B. (2005) · Chemistry and Physics of Lipids · doi:10.1016/j.chemphyslip.2005.06.005 · Cited by 48
Rapid induction of intraneuronal neurofibrillary tangles in apolipoprotein E-deficient mice
Bi, X., Yong, A. P., Zhou, J., Ribak, C. E., & Lynch, G. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151253098 · Cited by 43
Apolipoprotein E4 allele frequency in Spanish Alzheimer and control cases
Adroer, R., Santacruz, P., Blesa, R., Pousa, S. L., Ascaso, C., & Oliva, R. (1995) · Neuroscience Letters · doi:10.1016/0304-3940(95)11480-k · Cited by 50
Olarte, L., Schupf, N., Lee, J. H., Tang, M.-X., Santana, V., Williamson, J., Maramreddy, P., Tycko, B., & Mayeux, R. (2006) · Archives of Neurology · doi:10.1001/archneur.63.11.1586 · Cited by 42
Variable phenotype of Alzheimer's disease with spastic paraparesis
Smith, M. J., Kwok, J. B. J., McLean, C. A., Kril, J. J., Broe, G. A., Nicholson, G. A., Cappai, R., Hallupp, M., Cotton, R. G. H., Masters, C. L., et al. (2001) · Annals of Neurology · doi:10.1002/1531-8249(200101)49:1<125::aid-ana21>3.0.co;2-1 · Cited by 108
Petralla, S., Panayotova, M., Franchina, E., Fricker, G., & Puris, E. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16070948 · Cited by 49
Tang, X., Initiative, F. T. A. D. N., Holland, D., Dale, A. M., & Miller, M. I. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-150262 · Cited by 42
“It has been suggested that the APOE 4 allele is associated with an increased risk for AD and an earlier age of AD onset [1] whereas the 2 allele of APOE is associated with a lower risk [37].”
Protective effect of the APOE-e3 allele in Alzheimer’s disease
de-Almada, B. V. P., de-Almeida, L. D., Camporez, D., de-Moraes, M. V. D., Morelato, R. L., Perrone, A. M. S., Belcavello, L., Louro, I. D., & de-Paula, F. (2012) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x2011007500151 · Cited by 42
“The e2 allele seems to represent a protective factor both for familial AD and for LOAD, although this protection is not observed in every population (12,13).”
BackgroundResultPrion Disease Induces Alzheimer Disease—Like Neuropathologic Changes
Tousseyn, T., Bajsarowicz, K., Sánchez, H., Gheyara, A., Oehler, A., Geschwind, M., DeArmond, B., & DeArmond, S. J. (2015) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0000000000000228 · Cited by 42
Raman, S., Brookhouser, N., & Brafman, D. A. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104788 · Cited by 42
Cognitive reserve and midlife vascular risk: Cognitive and clinical outcomes
Soldan, A., Pettigrew, C. A., Zhu, Y., Wang, M., Gottesman, R. F., DeCarli, C. S., & Albert, M. (2020) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51120 · Cited by 45
The Role of Ethnicity in Alzheimer’s Disease: Findings From The C-PATH Online Data Repository
Chen, H.-Y., & Panegyres, P. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-151089 · Cited by 43
“Although some studies reported that ApoE ε 2 may have some protective effects on late onset AD [38, 39], interaction between ApoE ε 2 and ethnicity may mask the true effect of ApoE ε 2.”
Estrogen use and brain metabolic change in older adults. A preliminary report
Rasgon, N., Small, G. W., Siddarth, P., Miller, K. J., Ercoli, L. M., Bookheimer, S. Y., Lavretsky, H., Huang, S. C., Barrio, J. R., & Phelps, M. E. (2001) · Psychiatry Research Neuroimaging · doi:10.1016/s0925-4927(01)00084-1 · Cited by 47
Self-citationLUPIEN, S. J., Lord, C., Sindi, S., Wilkinson, C. W., & Fiocco, A. J. (2009) · Elsevier eBooks · doi:10.1016/b978-008088783-8.00097-8 · Cited by 43
Wısnıewskı, T., Morelli, L., Wegiel, J., Levy, E., Wı́sniewski, H. M., & Frangione, B. (1995) · Annals of Neurology · doi:10.1002/ana.410370128 · Cited by 42
Tsuang, D., Larson, E. B., Bowen, J., McCormick, W., Teri, L., Nochlin, D., Leverenz, J. B., Peskind, E. R., Lim, A., Raskind, M. A., et al. (1999) · Archives of Neurology · doi:10.1001/archneur.56.12.1489 · Cited by 42
Ionizing radiation and genetic risks
Sankaranarayanan, K., Chakraborty, R., & Boerwinkle, E. (1999) · Mutation Research/Reviews in Mutation Research · doi:10.1016/s1383-5742(98)00017-9 · Cited by 48
The βA4 Amyloid Precursor Protein Gene and Alzheimer's Disease
Hendriks, L., & Broeckhoven, C. V. (1996) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1996.0006n.x · Cited by 44
Moreno–Grau, S., Rodríguez‐Gómez, O., Sanabria, Á., Pérez‐Cordón, A., Sánchez‐Ruiz, D., Abdelnour, C., Valero, S., Hernández, I., Rosende‐Roca, M., Mauleón, A., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2017.10.005 · Cited by 41
“30e24] was unexpected taking into account the protective role of APOE ε2 in AD [34].”
Haβ, S., Fresser, F., Ko¨chl, S., Beyreuther, K., Utermann, G., & Baier, G. (1998) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)57838-3 · Cited by 41
Plasma β‐Amyloid Peptide, Transforming Growth Factor‐β1, and Risk for Cerebral Amyloid Angiopathy
Greenberg, S. M., CHO, H., O’Donnell, H. C., Rosand, J. M., Segal, A. Z., Younkin, L. H., Younkin, S. G., & Rebeck, G. W. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06361.x · Cited by 45
Inferior Temporal Lobe Atrophy and APOE Genotypes in Alzheimer’s Disease
Tanaka, S., Kawamata, J., Shimohama, S., Akaki, H., Akiguchi, I., Kimura, J., & Ueda, K. (1998) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000017029 · Cited by 44
Apolipoprotein E and multiple sclerosis: A biochemical and genetic investigation
Gaillard, O., Gervais, A., Meillet, D., Plassart, E., Fontaine, B., Lyon‐Caen, O., Delattre, J., & Schuller, E. (1998) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(98)00118-x · Cited by 43
Intracerebral hemorrhage: update
Labovitz, D. L., & Sacco, R. L. (2001) · Current Opinion in Neurology · doi:10.1097/00019052-200102000-00016 · Cited by 43
Apolipoprotein E Genotype e2: Neuroprotection and Its Limits
Kim, H., Devanand, D. P., Carlson, S., & Goldberg, T. E. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.919712 · Cited by 44
Mining Natural Variation for Maize Improvement: Selection on Phenotypes and Genes
Sood, S., Flint-Garcia, S. A., Willcox, M. C., & Holland, J. B. (2013) · Springer eBooks · doi:10.1007/978-94-007-7572-5_25 · Cited by 45
“Originally developed to identify genes involved in human diseases (Kerem et al. 1989; Corder et al. 1994), association mapping has become increasingly popular in plants in the last decade (Hauser et al.”
BackgroundFujishima, M., Kawaguchi, A., Maikusa, N., Kuwano, R., Iwatsubo, T., Matsuda, H., (ADNI), F. T. J. A. D. N. I., & (J-ADNI), T. J. A. D. N. I. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160621 · Cited by 43
“ApoE ε2 may protect against AD development [51].”
BackgroundTokgöz, S., & Claassen, J. A. H. R. (2021) · Cardiology and Therapy · doi:10.1007/s40119-020-00209-z · Cited by 42
“onset AD increases with the presence of one or two APOE e4 alleles [7].”
BackgroundHenningfield, C. M., Arreola, M. A., Soni, N., Spangenberg, E. E., & Green, K. N. (2022) · Glia · doi:10.1002/glia.24105 · Cited by 40
Imaging studies and APOE genotype in persons at risk for Alzheimer’s disease
Scarmeas, N., & Stern, Y. (2006) · Current Psychiatry Reports · doi:10.1007/s11920-006-0076-1 · Cited by 46
“The ε4 allele has a dose-related effect on risk for sporadic AD, whereas the ε2 allele seems to confer protection [4].”
BackgroundBONDI, M. W., HOUSTON, W. S., SALMON, D. P., COREY-BLOOM, J., KATZMAN, R., THAL, L. J., & DELIS, D. C. (2003) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617703950119 · Cited by 40
“…as a major risk factor for late-onset AD (Corder et al., 1993; Saunders et al., 1993; Strittmatter et al., 1993, 1994), but there is evidence that the associated risk wanes with advancing age (Corder et al., 1994, 1995, 1996; Rebeck et al., 1994; but see Gebner et al., 1997; Payami et al., 1997).”
BackgroundMulder, M., & Terwel, D. (1998) · Pathophysiology of Haemostasis and Thrombosis · doi:10.1159/000022429 · Cited by 40
Apolipoprotein E and Alzheimer's disease: the implications of progress in molecular medicine.
Mayeux, R., & Schupf, N. (1995) · American Journal of Public Health · doi:10.2105/ajph.85.9.1280 · Cited by 40
Pharmacogenomics for the treatment of dementia
Cacabelos, R. (2002) · Annals of Medicine · doi:10.1080/078538902320772115 · Cited by 42
Yang, S., Magnutzki, A., Alami, N. O., Lattke, M., Hein, T. M., Scheller, J. S., Kröger, C., Oswald, F., Yilmazer‐Hanke, D., Wirth, T., et al. (2021) · Cells · doi:10.3390/cells10102669 · Cited by 44
“In addition to apolipoprotein E (ApoE, risk allele ε4) [54,55], these include the triggering receptor expressed on myeloid cell 2 (TREM2), complement receptor 1 (CR1), ATP-binding cassette sub-family A membrane 7 (ABCA7), CD33, and various other risk genes [53,56–58].”
BackgroundThe vascular contribution of apolipoprotein E to Alzheimer’s disease
Chen, F., Zhao, J., Meng, F., He, F., Ni, J., & Fu, Y. (2024) · Brain · doi:10.1093/brain/awae156 · Cited by 41
Multi-functional role of apolipoprotein E in neurodegenerative diseases
Islam, S., Noorani, A. A., Sun, Y., Michikawa, M., & Zou, K. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1535280 · Cited by 47
Lyall, D. M., Royle, N. A., Harris, S. E., Bastin, M. E., Maniega, S. M., Murray, C., Lutz, M. W., Saunders, A. M., Roses, A. D., del Valdés Hernández, M. C., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0080513 · Cited by 39
“The ε4 allele is the deleterious ‘risk’ variant for cognitive ageing [9] and diagnosis of AD [10] compared with ε3 (‘neutral’), and ε2 (putatively ‘protective’).”
Self-citationProgressive medial temporal lobe atrophy during preclinical Alzheimer's disease
Pettigrew, C. A., Soldan, A., Sloane, K. L., Cai, Q., Wang, J., Wang, M., Moghekar, A., Miller, M. I., & Albert, M. (2017) · NeuroImage Clinical · doi:10.1016/j.nicl.2017.08.022 · Cited by 45
“Analyses including APOE carrier status excluded n= 5 individuals with the ε2/ε4 genotype given the ε4 allele increases AD dementia risk (Corder et al., 1993), whereas the ε2 allele decreases AD dementia risk (Corder et al., 1994).”
BackgroundMyelin repair in Alzheimer’s disease: a review of biological pathways and potential therapeutics
Hirschfeld, L. R., Risacher, S. L., Nho, K. T., & Saykin, A. J. (2022) · Translational Neurodegeneration · doi:10.1186/s40035-022-00321-1 · Cited by 45
“In fact, the ε2 allele has been shown to be protective against AD [52, 53] and is associated with higher myelin content compared to noncarriers, as observed via MWF [15].”
BackgroundMeta-analysis of association between ApoE ε4 allele and schizophrenia
Xu, M., Clair, D. S., & He, L. (2006) · Schizophrenia Research · doi:10.1016/j.schres.2006.02.015 · Cited by 39
“In addition, q4-carriers have an earlier onset of AD, compared with q3/3 genotype (Soininen and Riekkinen, 1996; Corder et al., 1994).”
BackgroundSrinivasan, R. (2006) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2005.063966 · Cited by 39
Petegnief, V., Saura, J., DeGregorio‐Rocasolano, N., & Paul, S. M. (2001) · Neuroscience · doi:10.1016/s0306-4522(01)00046-x · Cited by 45
Zwemmer, J., van Veen, T., van Winsen, L. M. L., van Kamp, G. J., Barkhof, F., Polman, C. H., & Uitdehaag, B. M. J. (2004) · Multiple Sclerosis Journal · doi:10.1191/1352458504ms1010oa · Cited by 38
Pettigrew, C., Soldan, A., Moghekar, A., Wang, M.-C., Gross, A. L., O’Brien, R., & Albert, M. (2015) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2015.09.024 · Cited by 38
Ali, J., Choe, K., Park, J. S., Park, H. Y., Kang, H., Park, T. J., & Kim, M.-O. (2024) · Antioxidants · doi:10.3390/antiox13070862 · Cited by 44
“Among these, the ε 4 allelic form of the APOE4 gene is the major genetic risk variant for LOAD, as identified via genome-wide association studies (GWAS) in patient/control cohort studies [36].”
Rao, A. T., Chen, N., Kim, M. J., Blumenfeld, J. R., Yip, O., Liang, Z., Shostak, D. M., Hao, Y., Nelson, M. R., Koutsodendris, N., et al. (2024) · Cell stem cell · doi:10.1016/j.stem.2024.10.005 · Cited by 49
Brain Functional Network in Alzheimer′s Disease: Diagnostic Markers for Diagnosis and Monitoring
Rodriguez, G., Arnaldi, D., & Picco, A. (2011) · International Journal of Alzheimer s Disease · doi:10.4061/2011/481903 · Cited by 43
“Indeed, ApoE2 has been suggested as having a protective effect and delaying the age of onset of AD [73, 74].”
BackgroundSapkota, S., Bäckman, L., & Dixon, R. A. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.12.022 · Cited by 42
“In contrast, the ε2 allele has been found to be protective in numerous studies (Corder et al., 1994; deAlmada et al., 2012; McFall et al., 2015a; Panza et al., 2000).”
ResultBesser, L. M., Galvin, J. E., Rodríguez, D. A., Seeman, T. E., Kukull, W. A., Rapp, S. R., & Smith, J. A. (2019) · Health & Place · doi:10.1016/j.healthplace.2019.102188 · Cited by 40
Association of ApoE and LRP mRNA levels with dementia and AD neuropathology
Akram, A., Schmeidler, J., Katsel, P., Hof, P. R., & Haroutunian, V. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.04.010 · Cited by 38
“ApoE 4 is also associated with an earlier age of AD onset (GomezIsla et al., 1996; Roses, 1996) relative to persons with the 2/ 3 genotype (Corder et al., 1993, 1994).”
BackgroundA Twin Study of the Genetic Contribution to Age-Related Functional Impairment
Gurland, B. J., Page, W. F., & Plassman, B. L. (2004) · The Journals of Gerontology Series A · doi:10.1093/gerona/59.8.m859 · Cited by 38
“Conversely, the e2 allele of APOE, which is associated with a reduced risk for Alzheimer’s disease (10), and the angiotensin-converting enzyme (ACE) DD genotype are both found more frequently in centenarians than in younger adults (11,12).”
BackgroundApolipoprotein E Genotype and Response of Carbon Monoxide Poisoning to Hyperbaric Oxygen Treatment
Hopkins, R. O., Weaver, L. K., Valentine, K. J., Mower, C. P., Churchill, S. K., & Carlquist, J. F. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200702-290oc · Cited by 37
“The e4 isoform generally has detrimental central nervous system effects (15), whereas e2 may be neuroprotective (19).”
A SCIENCE OF THE INDIVIDUAL: Implications for a Medical School Curriculum
Childs, B., Wiener, C., & Valle, D. L. (2005) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev.genom.6.080604.162345 · Cited by 42
“The list of SNPs with functional significance contributing to complex traits is growing daily and includes the P12A polymorphism of PPARγ that contributes to type I diabetes (1, 24), the factor V Leiden polymorphism that increases the risk for deep-venous thrombosis (38, 58), the chemokine receptor 5 (CCR5) variants a…”
BackgroundMaezawa, I., Zaja-Milatovic, S., Milatovic, D., Stephen, C., Sokal, I., Maeda, N., Montine, T. J., & Montine, K. S. (2006) · Journal of Neuroinflammation · doi:10.1186/1742-2094-3-21 · Cited by 38
“Humans, unlike other mammals, have 3 common alleles of the apolipoprotein (apo) E gene (APOE), the ε2 (APOE2), ε3 (APOE3), and ε4 (APOE4) alleles [19], and inheritance of APOE4 is associated with increased risk, earlier onset, or poorer clinical outcome for a number of neurologic diseases that broadly overlap with tho…”
BackgroundReelin in Alzheimer’s Disease, Increased Levels but Impaired Signaling: When More is Less
Cuchillo‐Ibáñez, I., Balmaceda, V., Mata‐Balaguer, T., López‐Font, I., & Sáez‐Valero, J. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-151193 · Cited by 37
“Interestingly, the neuroprotective ApoE2 ligand drives the strongest accumulation of C-terminal ApoER2 fragments compared with the AD-associated ApoE4 [135], which did not produce significant accumulation of intracellular ApoER2 [55].”
Molecular Pathology of Alzheimer’s Disease and Related Disorders
Ginsberg, S. D., Schmidt, M. L., Crino, P. B., Eberwine, J. H., Lee, V. M. ‐., & Trojanowski, J. Q. (1999) · Cerebral cortex · doi:10.1007/978-1-4615-4885-0_17 · Cited by 40
Morris, C. M., Benjamin, R., Leake, A., McArthur, F. K., Candy, J. M., Ince, P. G., Torvik, A., Bjertness, E., & Edwardson, J. A. (1995) · Neuroscience Letters · doi:10.1016/0304-3940(94)12126-b · Cited by 38
Salehi, A., Martinez, V., & Swaab, D. F. (1998) · Neurobiology of Aging · doi:10.1016/s0197-4580(98)00106-7 · Cited by 40
Association of apolipoprotein E polymorphism to clinical heterogeneity of multiple sclerosis
Ballerini, C., Campani, D., Rombolà, G., Gran, B., Nacmias, B., Amato, M. P., Siracusa, G., Bartolozzi, L., Sorbi, S., & Massacesi, L. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(00)01646-3 · Cited by 41
Predictors of Healthy Brain Aging
McNeal, M. G., Zareparsi, S., Camicioli, R., Dame, A., Howieson, D., Quinn, J., Ball, M., Kaye, J., & Payami, H. (2001) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/56.7.b294 · Cited by 38
“The lack of a significant effect on AD may be partly due to smaller numbers of AD cases, and partly due to a weakening effect of 4 on cognitive decline at higher ages (28).”
BackgroundCalero, O., Bullido, M. J., Clarimón, J., Frank, A., Martínez‐Martín, P., Lleó, A., Rey, M. J., Rábano, A., Blesa, R., Gómez‐Isla, T., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022090 · Cited by 41
“e2 carriers compared to non-e2 carriers (76.8±10.8 years vs. 74.3±8.0 years, p”
BackgroundInfluentialPekkala, T., Hall, A., Lötjönen, J. M. P., Mattila, J., Soininen, H. S., Ngandu, T., Laatikainen, T. K., Kivipelto, M., & Solomon, A. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160560 · Cited by 43
“APOE was modeled as a dichotomous variable ( 4 allele carrier/non-carrier), and also as an ordered variable (genotype 23 < 24 and 33 < 34 < 44) [35, 36].”
MethodTargeted Sequencing of Alzheimer Disease Genes in African Americans Implicates Novel Risk Variants
Logue, M. W., Lancour, D., Farrell, J., Simkina, I., Fallin, M. D., Lunetta, K. L., & Farrer, L. A. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00592 · Cited by 37
Modeling Alzheimer’s disease with human iPS cells: advancements, lessons, and applications
Essayan-Perez, S., Zhou, B., Nabet, A. M., Wernig, M., & Huang, Y. A. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104503 · Cited by 45
Apolipoprotein E isoform-dependent effects on the processing of Alzheimer's amyloid-β
Chai, A. B., Lam, H. H. J., Kockx, M., & Gelissen, I. C. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2021.158980 · Cited by 45
Does possession of apolipoprotein E ɛ4 benefit cognitive function in healthy young adults?
Bunce, D. J., Anstey, K. J., Burns, R. A., Christensen, H. M., & Easteal, S. (2011) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2011.02.042 · Cited by 48
Kurz, A., Altland, K., Lautenschlager, N. T., Zimmer, R., Busch, R. M., Gerundt, I., Lauter, H., & M�ller, U. (1996) · Journal of Neurology · doi:10.1007/bf00900498 · Cited by 47
“While the e4 allele is generally acknowledged as an important risk factor, it is unclear to date whether the a2 allele reduces [6] or increases the risk for AD [33].”
BackgroundResultSetzer, M., Hermann, E. J., Seifert, V., & Marquardt, G. (2008) · Spine · doi:10.1097/brs.0b013e3181657cf7 · Cited by 40
“Unlike 4, the 2 allele seems to act as protection factor for the occurrence of some neurologic diseases.(50,51) However, due to the low frequency of 2 compared with 3 and 4 in the population and the low number in our patient Table 4.”
BackgroundHandley, O., Morrison, C. M., Miles, C., & Bayer, A. J. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.08.001 · Cited by 42
Gilbert, P. E., & Murphy, C. (2004) · Experimental Gerontology · doi:10.1016/j.exger.2004.01.001 · Cited by 40
Scott, W. K., Yamaoka, L. H., Bass, M. P., Small, G. W., Farrer, L. A., Gaskell, P. C., Conneally, P. M., Saunders, A. M., Roses, A. D., Auerbach, S. H., et al. (1998) · Neurogenetics · doi:10.1007/s100480050026 · Cited by 43
“set AD [11, 12], but the role of APOE-2 in early-onset sporadic AD is less clear [13–15].”
BackgroundSelf-citationRoks, G., Cruts, M., Bullido, M. J., Backhovens, H., Artiga, M. J., Albert Hofman, D., Valdivieso, F., Broeckhoven, C. V., & van Duijn, C. M. (1998) · Neuroscience Letters · doi:10.1016/s0304-3940(98)00857-x · Cited by 37
Sun, G. G., Wang, C., Mazzarino, R. C., Perez-Corredor, P. A., Davtyan, H., Blurton-Jones, M., Lopera, F., Arboleda-Velasquez, J. F., & Shi, Y. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114982 · Cited by 36
Genetic Factors Affecting Late-Onset Alzheimer’s Disease Susceptibility
Rezazadeh, M., Khorrami, A., Yeghaneh, T., Talebi, M., Kiani, S. J., Heshmati, Y., & Gharesouran, J. (2015) · NeuroMolecular Medicine · doi:10.1007/s12017-015-8376-4 · Cited by 37
“In Seshadri et al. study, three-stage meta-analysis (8,371 LOAD cases and 26,965 controls) on variant rs744373 offered the strongest association with LOAD after ApoE, CLU, and PICALM (p = 1.6 9 10-11, OR 1.15) (Seshadri et al. 2010).”
InfluentialBeaton, D., Initiative, A. D. N., Dunlop, J. P., & Abdi, H. (2015) · Psychological Methods · doi:10.1037/met0000053 · Cited by 38
“Furthermore, " ApoE E4 " gene alleles are considered risk factors for Alzheimer's disease, whereas " ApoE E2 " gene alleles are considered protective against Alzheimer's disease (Corder et al., 1994).”
BackgroundChhibber, A., & Zhao, L. (2017) · Alzheimer s Research & Therapy · doi:10.1186/s13195-017-0305-3 · Cited by 40
“In contrast, possession of the ApoE2 allele has been reported to reduce the risk of LOAD by 50% [13, 17].”
BackgroundApolipoprotein E Genotypes, Age, Race, and Cognitive Decline in a Population Sample
Rajan, K. B., Barnes, L. L., Wilson, R. S., Weuve, J., McAninch, E. A., & Evans, D. A. (2018) · Journal of the American Geriatrics Society · doi:10.1111/jgs.15727 · Cited by 41
Epigenetic basis of Alzheimer disease
Tecalco-Cruz, Á. C., Ramírez‐Jarquín, J. O., Álvarez-Sánchez, M. E., & Zepeda–Cervantes, J. (2020) · World Journal of Biological Chemistry · doi:10.4331/wjbc.v11.i2.62 · Cited by 39
Sojkova, J., & M. Resnick, S. (2011) · Current Alzheimer Research · doi:10.2174/156720511795745375 · Cited by 36
“On the other hand, individuals with APOE ε2 allele have been shown to have low levels of PiB retention[25], consistent with known protective effects of APOE ε2 allele on risk for AD[70, 71].”
Evolution of senescence: Alzheimer's disease and evolution
Charlesworth, B. (1996) · Current Biology · doi:10.1016/s0960-9822(02)00411-6 · Cited by 37
Biological Markers in Alzheimer Disease
Neugroschl, J. A., & Davis, K. L. (2002) · American Journal of Geriatric Psychiatry · doi:10.1097/00019442-200211000-00005 · Cited by 42
Preventing Schizophrenia and Psychotic Behaviour: Definitions and Methodological Issues
Faraone, S. V., Brown, C. H., Glatt, S. J., & Tsuang, M. T. (2002) · The Canadian Journal of Psychiatry · doi:10.1177/070674370204700604 · Cited by 41
The Impact of Apolipoprotein E (APOE) Epigenetics on Aging and Sporadic Alzheimer’s Disease
Lozupone, M., Dibello, V., Sardone, R., Castellana, F., Zupo, R., Lampignano, L., Bortone, I., Daniele, A., Bellomo, A., Solfrizzi, V., et al. (2023) · Biology · doi:10.3390/biology12121529 · Cited by 41
“Conversely, in sporadic AD, the APOE allele ε 2, associated to the ApoE2 isoform, could have a protective effect [17,18].”
BackgroundNwabuisi-Heath, E., Rebeck, G. W., LaDu, M. J., & Yu, C. (2014) · ASN Neuro · doi:10.1042/an20130043 · Cited by 35
“In contrast, APOE2 reduces AD risk 2- and 4-fold (Corder et al., 1994).”
BackgroundNyine, M., Uwimana, B., Akech, V., Brown, A., Ortiz, R. O., Doležel, J., Lorenzen, J. H., & Swennen, R. L. (2019) · Theoretical and Applied Genetics · doi:10.1007/s00122-019-03425-x · Cited by 37
Qin, W., Li, W., Wang, Q., Gong, M., Li, T., Shi, Y., Song, Y., Li, Y., Li, F., & Jia, J. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210549 · Cited by 42
“Whereas carrying the (cid:2) 4 allele increases one’s risk of developing AD, the (cid:2) 2 allele has a putative protective effect associated with longevity and lower AD risk [3–5].”
Blackman, J., Love, S., Sinclair, L. I., Cain, R., & Coulthard, E. J. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-00992-y · Cited by 41
“However, whilst possession of ε2 reduces the odds of developing AD [37, 38], this allele has been linked with increased likelihood of OSA [39].”
BackgroundAPOE genetic associations with seizure development after severe traumatic brain injury
Miller, M. A., Conley, Y. P., Scanlon, J. M., Ren, D., Kamboh, M. I., Niyonkuru, C., & Wagner, A. K. (2010) · Brain Injury · doi:10.3109/02699052.2010.520299 · Cited by 39
“In the past, studies of AD have found evidence that the E2 allele is less frequent in AD subjects than what would have been predicted from normal population frequency studies [50, 51].”
ResultThe neurobiology of APOE in schizophrenia and mood disorders
Gibbons, A. S. (2011) · Frontiers in Bioscience · doi:10.2741/3729 · Cited by 35
“Most notably the APOE polymorphic variant, APOEε4 is associated with a dramatically increase in the risk of developing Alzheimer’s disease (AD) (7) and decreasing the age of onset (8), while allele APOEε2 is negatively associated with development of AD (9).”
BackgroundDiminished neuronal metabolic activity in Alzheimer's disease
Salehi, A., & Swaab, D. F. (1999) · Journal of Neural Transmission · doi:10.1007/s007020050216 · Cited by 38
“Few ApoE ε4/4 individuals reach the age of 90 years without developing AD (Saunders et al., 1993; Corder et al., 1994; Rebeck et al., 1994; Schächter et al., 1994).”
BackgroundBlain, J.-F., Sullivan, P. M., & Poirier, J. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.08.010 · Cited by 35
“ApoE2 reduces the risk of Alzheimer’s disease (AD) (Corder et al., 1994) and delays its onset by nearly 20 years.”
BackgroundMinowa, T., Ohtsuka, S., Sasai, H., & Kamada, M. (2000) · Electrophoresis · doi:10.1002/(sici)1522-2683(20000501)21:9<1755::aid-elps1755>3.0.co;2-s · Cited by 19
Apolipoprotein E e4 allele frequency in patients with multiple system atrophy
Cairns, N. J., Atkinson, P. F., Kovács, T., Lees, A. J., Daniel, S. E., & Lantos, P. L. (1997) · Neuroscience Letters · doi:10.1016/s0304-3940(96)13316-4 · Cited by 35
Apolipoprotein E in the genetics and epidemiology of Alzheimer's disease
Hardy, J. (1995) · American Journal of Medical Genetics · doi:10.1002/ajmg.1320600519 · Cited by 39
Apolipoprotein E and Alzheimer's disease: a genetic, molecular and neuroimaging review.
Swartz, R. H., Black, S. E., & George‐Hyslop, P. S. (1999) · PubMed · Cited by 46
Kunkle, B., Grenier-Boley, B., Sims, R., Bis, J., Naj, A., Boland, A., Vronskaya, M., van der Lee, S., Amlie-Wolf, A., Bellenguez, C., et al. (2018) · doi:10.1101/294629 · Cited by 35
Self-citationRuzali, W. A. W., Kehoe, P. G., & Love, S. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-121336 · Cited by 34
“APOE 4 is a major risk factor for late-onset AD [28–31] and CAA [32, 33].”
BackgroundHostage, C. A., Choudhury, K. R., Doraiswamy, P. M., Petrella, J. R., & Initiative, A. D. N. (2014) · Radiology · doi:10.1148/radiol.13131041 · Cited by 41
“Ad-ditionally, although APOE ´ 2 did show (50).”
Metadata
- Authors
- Corder, E. H., Saunders, A. M., Risch, N. J., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Rimmler, J. B., Locke, P. A., Conneally, P. M., Schmader, K. E., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A.
- Affiliations
- Duke University (US)
- Yale University (US)
- Massachusetts General Hospital (US)
- Indiana University School of Medicine (US)
- University of California, Los Angeles (US)
- Venue
- Nature Genetics
- Published
- 1994-06
- Volume
- 7
- Issue
- 2
- Pages
- 180-184
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W2090271811
- Cited by
- 1,920
- References
- 41
- Citations by year
- 2026: 45 · 2025: 77 · 2024: 78 · 2023: 59 · 2022: 66 · 2021: 76 · 2020: 76 · 2019: 58 · 2018: 62 · 2017: 58 · 2016: 75 · 2015: 55 · 2014: 63 · 2013: 68 · 2012: 66
- FWCI
- 54.52
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (NIA AG05128, U24AG021886)
- National Institute of Neurological Disorders and Stroke (P01NS026630, NINDS NS26630, NINDS NS531153)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- apolipoprotein E, APOE ε4, late-onset Alzheimer's disease, familial Alzheimer's disease, gene dosage, protective effect, sporadic Alzheimer's disease, genetic risk factors, APOE genotype
- MeSH terms
- Aged, Alleles, Alzheimer Disease, Apolipoproteins E, Female, Gene Frequency, Genotype, Humans, Male, Middle Aged, Risk Factors, Odds Ratio, Age of Onset
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.